Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

被引：0
|
作者：
Stephen K. Tyring
Phoebe Rich
Yayoi Tada
Stefan Beeck
Izabella Messina
Jie Liu
Xiaohong Huang
Stephen Shumack
机构：
[1] University of Texas Health Science Center,Department of Dermatology, McGovern Medical School
[2] Oregon Health and Science University,undefined
[3] Teikyo University School of Medicine,undefined
[4] AbbVie Inc.,undefined
[5] St George Dermatology and Skin Cancer Centre,undefined
来源：
Dermatology and Therapy | 2023年 / 13卷
关键词：
Atopic dermatitis; Interleukin-23; Risankizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：595 / 608
页数：13
相关论文
共 50 条
  • [1] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Tyring, Stephen K. K.
    Rich, Phoebe
    Tada, Yayoi
    Beeck, Stefan
    Messina, Izabella
    Liu, Jie
    Huang, Xiaohong
    Shumack, Stephen
    DERMATOLOGY AND THERAPY, 2023, 13 (02) : 595 - 608
  • [2] The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study
    Zhao, Y.
    Wu, L.
    Lu, Q.
    Gao, X.
    Zhu, X.
    Yao, X.
    Li, L.
    Li, W.
    Ding, Y.
    Song, Z.
    Liu, L.
    Dang, N.
    Zhang, C.
    Liu, X.
    Gu, J.
    Wang, J.
    Geng, S.
    Liu, Q.
    Guo, Y.
    Dong, L.
    Su, H.
    Bai, L.
    O'Malley, J. T.
    Luo, J.
    Laws, E.
    Mannent, L.
    Ruddy, M.
    Amin, N.
    Bansal, A.
    Ota, T.
    Wang, M.
    Zhang, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 633 - 641
  • [3] Efficacy and Safety of Baricitinb in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
    Torrelo, A.
    Rewerska, B.
    Paller, Amy
    Prakash, A.
    Zhu, D.
    Pontes, M.
    Wu, Wen-Shuo
    Eichenfield, Lawrence F.
    Boecker, Ulrike
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 99 - 99
  • [4] Efficacy and Safety of GR1802 in Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
    Wang, Shangshang
    Zhang, Litao
    Liang, Yunsheng
    Zhang, Shifa
    Wang, Jingyan
    Man, Xiaoyong
    Ji, Chao
    Chen, Rixin
    Xiang, Guang
    Meng, Zudong
    Yang, Chunjun
    Cheng, Hao
    Wang, Qi
    Li, Lin-feng
    Zhang, Siping
    Ding, Yanfeng
    Zhu, Quangang
    Qin, Lanying
    Li, Yumei
    Lu, Qianjin
    Xia, Li
    Cao, Shuanglin
    Yu, Chunshui
    Duan, Xinsuo
    Wu, Liming
    Zhang, Chunlei
    Jiang, Congjun
    Wang, Wei
    Xu, Jinhua
    DERMATOLOGIC THERAPY, 2025, 2025 (01)
  • [5] Dupilumab Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study
    Bieber, Thomas R. M.
    Thaci, Diamant
    Graham, Neil
    Pirozzi, Gianluca
    Teper, Ariel
    Ren, Haobo
    Radin, Allen
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB404 - AB404
  • [6] Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis:: a randomized, double-blind, placebo-controlled trial
    Berth-Jones, J.
    Arkwright, P. D.
    Marasovic, D.
    Savani, N.
    Aldridge, C. R.
    Leech, S. N.
    Morgan, C.
    Clark, S. M.
    Ogilvie, S.
    Chopra, S.
    Harper, J. I.
    Smith, C. H.
    Rook, G. A. W.
    Friedmann, P. S.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2006, 36 (09): : 1115 - 1121
  • [7] A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease
    Targan, Stephan R.
    Feagan, Brian
    Vermeire, Severine
    Panaccione, Remo
    Melmed, Gil Y.
    Landers, Carol
    Li, Dalin
    Russell, Chris
    Newmark, Richard
    Zhang, Nan
    Chon, Yun
    Hsu, Yi-Hsiang
    Lin, Shao-Lee
    Klekotka, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (11): : 1599 - 1607
  • [8] Results from a randomized, double-blind, placebo-controlled, exploratory, multicenter study of GBR 830 in adult patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, Emma
    Pavel, Ana B.
    Estrada, Yeriel
    Zhang, Ning
    Peng, Xiangyu
    Xu, Hui
    Wen, Huei-Chi
    Fang, Hui
    Salhi, Yacine
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB245 - AB245
  • [9] Rocatinlimab significantly improves clinical responses in patients with moderate-to-severe atopic dermatitis by week 2 in a randomized double-blind placebo-controlled phase 2b study
    Guttman-Yassky, Emma
    Esfandiari, Ehsanollah
    Mano, Hirotaka
    Arai, Takahiro
    Kabashima, Kenji
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [10] Results from a phase IIa randomized, double-blind, placebo-controlled, exploratory, multicentre study of GBR 830 in adults with moderate-to-severe atopic dermatitis
    Guttman-Yassky, E.
    Pavel, A.
    Estrada, Y.
    Zhang, N.
    Peng, X.
    Xu, H.
    Wen, H.
    Fang, H.
    Salhi, Y.
    Gudi, G.
    Ca, V.
    Gn, S.
    Grossman, F.
    Wolff, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (01) : E44 - E45
12345